CompletedPhase 3NCT01645189

Safety and Efficacy of Hunterase

Studying Mucopolysaccharidosis type 2

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Green Cross Corporation
Principal Investigator: Dong-Kyu Jin
Samsung medical center, Seoul, Republic of Korea
Intervention: Hunterase(biological)
Enrollment: 6 enrolled
Eligibility: 5 years · MALE
Timeline: 2012 – 2013

Study locations (1)

Samsug Medical Center, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01645189 on ClinicalTrials.gov

Other trials for Mucopolysaccharidosis type 2

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06031259
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment
Takeda

See all trials for Mucopolysaccharidosis type 2 →

← Back to all trials